Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Ertugliflozin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 7,453Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Hikma Pharma`s Generics Ertugliflozin Receives Approval in US
    Hikma Pharma`s Generics Ertugliflozin Receives Approval in US

    21 Jan 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216842

    FDA
    21 Jan 2025
    Share Share
    Hetero Labs Generic Ertugliflozin Receives Tentative Approval in US
    Hetero Labs Generic Ertugliflozin Receives Tentative Approval in US

    17 Apr 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217071

    FDA
    17 Apr 2024
    Share Share
    Zenara's Generic Ertugliflozin Receives Approval in the U.S.
    Zenara's Generic Ertugliflozin Receives Approval in the U.S.

    04 Apr 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216842

    FDA
    04 Apr 2023
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Ertugliflozin
    FDA Confirms Paragraph IV Patent Litigation for Ertugliflozin

    08 Feb 2022

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-ertugliflozin-1646027922.pdf

    FDA
    08 Feb 2022
    Share Share
    Ertugliflozin Reduces Likelihood of Insulin Initiation in Insulin-Naive Patients
    Ertugliflozin Reduces Likelihood of Insulin Initiation in Insulin-Naive Patients

    29 Jun 2021

    // FIRSTWORDPHARMA

    https://www.firstwordpharma.com/node/1841963?tsid=4

    FIRSTWORDPHARMA
    29 Jun 2021
    Share Share
    Merck's Steglatro shows limited promise with heart failure hospitalization data
    Merck's Steglatro shows limited promise with heart failure hospitalization data

    31 Aug 2020

    // Kyle Blankenship FIERCEPHARMA

    https://www.fiercepharma.com/pharma/esc-merck-s-steglatro-makes-case-for-heart-failure-new-hospitalization-data

    Kyle Blankenship FIERCEPHARMA
    31 Aug 2020
    Share Share